TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01854047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levosalbutamol/levalbuterol
Description: Oral inhalation as needed

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levosalbutamol/levalbuterol
Description: Oral inhalation as needed
Study: NCT00076622

Intervention type: DRUG
Intervention: Antidepressant medication
Description: Participants assigned to continue current medication will be monitored over a period of one year for recurrence of depression and related symptoms.

Intervention type: DRUG
Intervention: Antidepressant medication
Description: Participants assigned to continue current medication will be monitored over a period of one year for recurrence of depression and related symptoms.

Intervention type: DRUG
Intervention: No antidepressant medication
Description: Participants assigned to discontinue current medication (no antidepressant medication) will be monitored over a period of one year for recurrence of depression and related symptoms.

Intervention type: DRUG
Intervention: No antidepressant medication
Description: Participants assigned to discontinue current medication (no antidepressant medication) will be monitored over a period of one year for recurrence of depression and related symptoms.
Study: NCT04140318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sintilimab
Description: Sintilimab 200mg, iv, 30-60min, q3w;
Study: NCT03553394

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringer's Acetate
Description: Will receive a fluid bolus immediately (Ringer's Acetate 5 mls/kg bw) if oliguric/anuric for two consecutive hours
Study: NCT04967131

Intervention type: OTHER
Intervention: PNF exercises
Description: PNF exercises were applied in 3 sets of 15 repetitions based on movement in the diagonal plane, using head, neck and chin patterns. Contractions were sustained for at least 10 seconds.
Study: NCT03464669

Intervention type: OTHER
Intervention: Prenatal education
Description: Observational study : natural distribution of participants between groups

Intervention type: OTHER
Intervention: Prenatal education
Description: Observational study : natural distribution of participants between groups
Study: NCT01903941

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Only Counseling
Study: NCT02604264

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ClearGuard HD end cap
Description: The ClearGuard HD End Cap elutes chlorhexidine acetate into the hemodialysis catheter hub
Study: NCT03696472

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: robotic assisted surgery
Description: robotic assisted surgery was benefit to operation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic
Description: conventional laparoscopic surgery
Study: NCT02050178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMP-54F28, Nab-Paclitaxel and Gemcitabine
Study: NCT04810728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extract Psidii guava
Description: 2 Capsule Extract Psidii guava, three times daily

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Standard therapy for Covid-19 patient
Description: (Vitamin C, Zinc, medication for clinical symptoms such as: antipyretic agent, decongestan and mucolytic.)

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Standard therapy for Covid-19 patient
Description: (Vitamin C, Zinc, medication for clinical symptoms such as: antipyretic agent, decongestan and mucolytic.)
Study: NCT01162798

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: infant formula
Description: test infant formula fed to infants until 6 months corrected gestational age

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control infant formula
Description: commercially available infant formula
Study: NCT01604278

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NVA237 50 µg and indacaterol 150 µg
Description: NVA237 50 µg and indacaterol 150 µg supplied as blistered capsules for inhalation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to NVA237 and indacaterol 150 µg
Description: Placebo to NVA237 and indacaterol 150 µg supplied as blistered capsules for inhalation.
Study: NCT02565134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAC-14028 cream 0.1%
Description: Topical application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAC-14028 cream 0.3%
Description: Topical application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAC-14028 cream 1.0%
Description: Topical application

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PAC-14028 cream vehicle
Description: Topical application
Study: NCT02793856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: To deplete Tregs before collecting peripheral blood

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: To deplete Tregs before collecting peripheral blood

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: To deplete Tregs before collecting peripheral blood

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PD-1 Knockout T Cells
Description: Autologous lymphocytes are collected and PDCD1 gene is knocked out in the laboratory. Cells are selected and expanded ex vivo. Cells are infused back to the patients for treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PD-1 Knockout T Cells
Description: Autologous lymphocytes are collected and PDCD1 gene is knocked out in the laboratory. Cells are selected and expanded ex vivo. Cells are infused back to the patients for treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PD-1 Knockout T Cells
Description: Autologous lymphocytes are collected and PDCD1 gene is knocked out in the laboratory. Cells are selected and expanded ex vivo. Cells are infused back to the patients for treatment
Study: NCT03680742

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contour Neurovascular System
Description: The Contour Neurovascular System™ is an intrasaccular, self-expanding, embolization device intended for the treatment of unruptured intracranial aneurysms.
Study: NCT02298335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Full-dose induction period: Prednisone 1mg/kg.day, maximum 60mg/day, orally, divided into 3 times; Protracted tapering period: orally, no ask for fract. dos.
Study: NCT01282970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 135585
Description: oral doses given to approximately 5-6 parallel groups of 12 subjects (9 on active and 3 on placebo) over 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to BI 135585
Description: oral doses given to approximately 5-6 parallel groups of 12 subjects (9 on active and 3 on placebo) over 14 days
Study: NCT00693862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levodopa, carbidopa, entacapone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levodopa, carbidopa
Study: NCT01701752

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FP-01.1 + Placebo

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FP-01.1 + TIV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FP-01.1-Adjuvant + Placebo

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FP-01.1-Adjuvant + TIV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvant + TIV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo + TIV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FP-01.1

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FP-01.1

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FP-01.1-Adjuvant

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FP-01.1-Adjuvant

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study: NCT00773227

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous myoblasts transplantation and myotomy
Description: Graft of autologous cell muscles (myoblasts) isolated from unaffected limb muscles into the pharyngeal muscles of patients diagnosed as suffering from OPMD and surgical procedure (myotomy)
Study: NCT03089762

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intra-articular injection of SVF plus PRP
Description: administering SVF and PRP intra-articularly into patients with osteoarthritis grade 1 and 2
Study: NCT00167297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Study: NCT00395057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN 211745
Description: AGN 211745 Solution 1000µg injection at Day 1, Month 1, Month 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN 211745
Description: AGN 211745 Solution 300µg injections, Day 1, Month 1, Month 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN 211745
Description: AGN 211745 Solution 100µg injections, Day 1, Month 1, Month 2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab 500µg
Description: Ranibizumab 500µg injections at Day 1, Month 1, Month 2
Study: NCT03086564

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ADCC & TACE
Description: Experimental groups will be given TACE as well as Activated-Dendritic Cells(1-2\*10\^8,intravenous drip),simultaneously.Cyclophosphamide(250mg/cm2,intravenous drip) will be used two days before TACE performed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TACE
Description: TACE solely in the first day of a clinical course.
Study: NCT04140318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: Nab-paclitaxel: 125 mg/m2 iv d1、d8, q3w
Study: NCT02096783

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: informational intervention
Description: Given scripted intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: informational intervention
Description: Given scripted intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: informational intervention
Description: Given scripted intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: counseling intervention
Description: Given standard counseling

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: counseling intervention
Description: Given standard counseling

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: counseling intervention
Description: Given standard counseling

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: counseling intervention
Description: Given standard counseling

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study: NCT03352245

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prescribed Activity
Description: Educational session at enrollment, increase subject communication via tailored electronic messaging, and use of a wrist-bound device (FitBit Flex 2)
Study: NCT02737865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sonazoid
Description: Sonazoid: Commercially available contrast material for ultrasonography

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Superb-Microvascular imaging
Description: Superb-Microvascular imaging: new sonographic software technique on ultrasonography to detect low-vascular flow without use of contrast media for ultrasonography
Study: NCT01559103

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI5117
Description: Intravenous infusion administered over 60 minutes, will be one of the following doses: 30, 100, 300, or 600 mg

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: MEDI5117 Placebo
Description: Intravenous infusion administered over 60 minutes
Study: NCT02835430

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronally advanced flap and PRF with DFDBA
Description: • For Test site: i. Following pre-suturing of coronally advanced flap, DFDBA (Rocky Mountain Particulate Allograft) was placed over the exposed root and adjacent bone surface and subsequently covered by PRF membrane.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronally advanced flap and PRF without DFDBA
Description: . For Control site: i. Following pre-suturing of coronally avanced flap, exposed root and adjacent bone surface was covered by PRF membrane.
Study: NCT03655444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Abemaciclib is an investigational agent for this trial and will be supplied by Lilly Oncology, free of charge to the patient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Abemaciclib is an investigational agent for this trial and will be supplied by Lilly Oncology, free of charge to the patient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is commercially available

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is commercially available

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor biopsy
Description: * Phase II patients only~* If the patient consents, fresh tumor tissue will be collected at baseline and then during Cycle 2 (between days 8-22) of abemaciclib and nivolumab.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral blood
Description: * Phase II patients only~* Peripheral blood will be collected at baseline, at the end of the Lead In (cycle 1 day 1 prior to treatment), during cycle 2 (between days 8-22), and during cycle 3 (between days 21-28). If patient does not have progression after cycle 3, patient will also have peripheral blood collected at time of progression.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EORTC QLQ-30
Description: * Phase II patients only~* Screening , Cycle 2 D1, Cycle 4 D1, and End of treatment (EOT)
Study: NCT03996772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban Oral Tablet
Description: Factor Xa Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran
Description: Direct Thrombin Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban Tablets
Description: Factor Xa Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: Factor Xa Inhibitor
Study: NCT03619629

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio-tape
Description: Kinesiotape will be applied both ankles as Correction technique.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mulligan's mobilization with movement
Description: 'Posterolateral glide mobilization with movement' will be applied 10 times to both ankles.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Kinesio-taping
Description: Sham Kinesio-taping technique will be applied both ankles.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Mulligan's mobilization with movement
Description: Sham Mulligan's mobilization with movement technique will be applied both ankles.
Study: NCT02420444

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG SSI
Description: The dose volume administered for BCG was 0.1 mL, and the mode of administration was ID injection to the deltoid area.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: BCG SSI
Description: The dose volume administered for BCG was 0.1 mL, and the mode of administration was ID injection to the deltoid area.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG SSI
Description: The dose volume administered for BCG was 0.1 mL, and the mode of administration was ID injection to the deltoid area.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This is the identical buffer solution in which H4:IC31 was formulated. The dose volume administered for Placebo was 0.5mL, and the mode of administration was an IM injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: This is the identical buffer solution in which H4:IC31 was formulated. The dose volume administered for Placebo was 0.5mL, and the mode of administration was an IM injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AERAS-404
Description: AERAS-404 vaccine was reconstituted on site by adding 0.2 mL H4 antigen solution to 0.8 mL IC31 adjuvant solution. The dose volume administered for AERAS-404 was 0.5mL, and the mode of administration was an IM injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AERAS-404
Description: AERAS-404 vaccine was reconstituted on site by adding 0.2 mL H4 antigen solution to 0.8 mL IC31 adjuvant solution. The dose volume administered for AERAS-404 was 0.5mL, and the mode of administration was an IM injection.
Study: NCT03401918

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Uterine ERA and microbiome testing
Description: Uterine fluid and endometrial biopsy collection to test uterine endometrial receptivity array and microbiome.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Uterine ERA and microbiome testing
Description: Uterine fluid and endometrial biopsy collection to test uterine endometrial receptivity array and microbiome.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral antibiotics and vaginal probiotics
Description: For subjects with abnormal microbiome results, oral antibiotics and vaginal probiotic treatment will be offered followed by a repeat uterine microbiome biopsy.
Study: NCT00672659

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Citalopram + Pipamperone
Description: Citalopram, 40 mg daily, 8 weeks Pipamperone, 5 mg twice daily, 8 weeks
Study: NCT02158663

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: TMS Device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: TMS Device
Study: NCT01286090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisapride
Description: One 10-mg tablet taken orally 4 times a day for up to 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One tablet taken orally 4 times a day for up to 8 weeks.
Study: NCT03892863

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: active repetitive transcranial magnetic stimulation
Description: High frequency rTMS to induce the long term potentiation in the left dorsolateral prefrontal cortex

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham repetitive transcranial magnetic stimulation
Description: High frequency rTMS to induce the long term potentiation in the left dorsolateral prefrontal cortex
Study: NCT00672659

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Citalopram
Description: Citalopram, 40 mg daily, 8 weeks Placebo, dummy, twice a day, 8 weeks
Study: NCT04193696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiation therapy and systemic anti-PD-1 immunotherapy for patients with advanced hepatocellular carcinoma
Description: The treatment will be started within 1 week after being admitted into the trial. IMRT or SBRT are adopted , and dose of radiation: Dt-PGTV=40Gy/10fractions,Dt-PGTV=30Gy/10fractions,Dt-PGTV=20Gy/10fractions ,and so on.200mg/ of Carelizumab for injection will be given intravenously every 3 weeks for 5 times since the first day of radiotherapy until disease progression, or intolerable toxicity.
Study: NCT02600403

Intervention type: DIAGNOSTIC_TEST
Intervention: Optical Coherence Tomography (OCT)
Description: Optical Coherence Tomography (OCT) is a machine that scans eyes and has the capability of measuring thickness of various layers of the retina and nerve fiber layer (NFL).

Intervention type: DIAGNOSTIC_TEST
Intervention: Optical Coherence Tomography (OCT)
Description: Optical Coherence Tomography (OCT) is a machine that scans eyes and has the capability of measuring thickness of various layers of the retina and nerve fiber layer (NFL).

Intervention type: DIAGNOSTIC_TEST
Intervention: Optical Coherence Tomography (OCT)
Description: Optical Coherence Tomography (OCT) is a machine that scans eyes and has the capability of measuring thickness of various layers of the retina and nerve fiber layer (NFL).

Intervention type: DIAGNOSTIC_TEST
Intervention: Visual evoked potential (VEP)
Description: Visual Evoked Potential (VEP) is an imaging system that measures electrical activity from the eye to the brain by using electrodes placed on forehead and back of the head similar to electroencephalogram (EEG).
Study: NCT03251131

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Restrictive fluid management
Description: Daily fluid input is restricted to drugs and nutrition. Fluid boluses and blood products can be given if clinically indicated. Matching fluid output to fluid input whenever possible using diuretics if needed, and additionally, if clinically necessary and plausible, commencing renal replacement therapy. If renal replacement therapy is not deemed clinically desirable, acceptance of a less than targeted fluid balance.
Study: NCT00472758

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MEDI 545
Description: IV dosed at 1.0 mg/kg, 3.0,g/kg, 10.0mg/kg and 30.0mg/kg
Study: NCT02600403

Intervention type: DIAGNOSTIC_TEST
Intervention: Visual evoked potential (VEP)
Description: Visual Evoked Potential (VEP) is an imaging system that measures electrical activity from the eye to the brain by using electrodes placed on forehead and back of the head similar to electroencephalogram (EEG).

Intervention type: DIAGNOSTIC_TEST
Intervention: Visual evoked potential (VEP)
Description: Visual Evoked Potential (VEP) is an imaging system that measures electrical activity from the eye to the brain by using electrodes placed on forehead and back of the head similar to electroencephalogram (EEG).

Intervention type: DIAGNOSTIC_TEST
Intervention: Humphrey Visual Field (HVF)
Description: Humphrey Visual Field (HVF) is a test done to evaluate how much peripheral (side) vision has been lost due to glaucoma.

Intervention type: DIAGNOSTIC_TEST
Intervention: Humphrey Visual Field (HVF)
Description: Humphrey Visual Field (HVF) is a test done to evaluate how much peripheral (side) vision has been lost due to glaucoma.

Intervention type: DIAGNOSTIC_TEST
Intervention: Humphrey Visual Field (HVF)
Description: Humphrey Visual Field (HVF) is a test done to evaluate how much peripheral (side) vision has been lost due to glaucoma.